Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle

M. J. Gounis, M. G. Spiga, Regina M Graham, A. Wilson, S. Haliko, B. B. Lieber, A. K. Wakhloo, Keith A Webster

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Therapeutic angiogenesis involves the introduction of exogenous growth factor proteins and genes into ischemic tissues to augment endogenous factors and promote new vessel growth. Positive results from studies in animal models of peripheral arterial disease (PAD) and coronary artery disease over the past decade have supported the implementation of clinical trials testing vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) proteins and genes. Although several clinical trials reported positive results, others have been disappointing and results of a recent Phase II trial of VEGF delivered by adenovirus (the RAVE trial) were negative. It has been suggested that the duration of gene expression following delivery by adenovirus may be insufficient to produce stable vessels. Here we present direct evidence in support of this using the rabbit ischemic hindlimb model injected with adenovirus encoding VEGF165. Immunohistology indicated an activation of endothelial cell cycling and proliferation 2-3 days after VEGF delivery that coincided closely with transient VEGF expression. Ki-67-positive endothelial nuclei were evident at high levels in capillaries and large vessels in muscles from treated animals. Angiography indicated increased density of both large and small vessels in Ad-VEGF-treated muscle at 1 week, but no significant differences thereafter. The early burst of endothelial proliferation was accompanied by increased nuclear fragmentation and condensation in VEGF-treated muscles, suggesting coincident apoptosis. No further endothelial cell proliferation took place after 1 week although there was still evidence of apoptosis. The results suggest that angiogenesis is confined to the short period of VEGF expression produced by adenovirus and early gains in collateralization rapidly regress to control levels when VEGF production ceases.

Original languageEnglish
Pages (from-to)762-771
Number of pages10
JournalGene Therapy
Volume12
Issue number9
DOIs
StatePublished - May 1 2005

Fingerprint

Vascular Endothelial Growth Factor A
Muscles
Adenoviridae
Genes
Endothelial Cells
Cell Proliferation
Clinical Trials
Apoptosis
Fibroblast Growth Factors
Peripheral Arterial Disease
Hindlimb
Coronary Artery Disease
Intercellular Signaling Peptides and Proteins
Angiography
Proteins
Animal Models
Rabbits
Gene Expression
Growth

Keywords

  • Claudication
  • Ischemia
  • Peripheral artery disease
  • Rabbit
  • Therapeutic angiogenesis

ASJC Scopus subject areas

  • Genetics

Cite this

Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. / Gounis, M. J.; Spiga, M. G.; Graham, Regina M; Wilson, A.; Haliko, S.; Lieber, B. B.; Wakhloo, A. K.; Webster, Keith A.

In: Gene Therapy, Vol. 12, No. 9, 01.05.2005, p. 762-771.

Research output: Contribution to journalArticle

Gounis, MJ, Spiga, MG, Graham, RM, Wilson, A, Haliko, S, Lieber, BB, Wakhloo, AK & Webster, KA 2005, 'Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle', Gene Therapy, vol. 12, no. 9, pp. 762-771. https://doi.org/10.1038/sj.gt.3302481
Gounis, M. J. ; Spiga, M. G. ; Graham, Regina M ; Wilson, A. ; Haliko, S. ; Lieber, B. B. ; Wakhloo, A. K. ; Webster, Keith A. / Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. In: Gene Therapy. 2005 ; Vol. 12, No. 9. pp. 762-771.
@article{12f3ec6562a64b54a425f7dd8748872e,
title = "Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle",
abstract = "Therapeutic angiogenesis involves the introduction of exogenous growth factor proteins and genes into ischemic tissues to augment endogenous factors and promote new vessel growth. Positive results from studies in animal models of peripheral arterial disease (PAD) and coronary artery disease over the past decade have supported the implementation of clinical trials testing vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) proteins and genes. Although several clinical trials reported positive results, others have been disappointing and results of a recent Phase II trial of VEGF delivered by adenovirus (the RAVE trial) were negative. It has been suggested that the duration of gene expression following delivery by adenovirus may be insufficient to produce stable vessels. Here we present direct evidence in support of this using the rabbit ischemic hindlimb model injected with adenovirus encoding VEGF165. Immunohistology indicated an activation of endothelial cell cycling and proliferation 2-3 days after VEGF delivery that coincided closely with transient VEGF expression. Ki-67-positive endothelial nuclei were evident at high levels in capillaries and large vessels in muscles from treated animals. Angiography indicated increased density of both large and small vessels in Ad-VEGF-treated muscle at 1 week, but no significant differences thereafter. The early burst of endothelial proliferation was accompanied by increased nuclear fragmentation and condensation in VEGF-treated muscles, suggesting coincident apoptosis. No further endothelial cell proliferation took place after 1 week although there was still evidence of apoptosis. The results suggest that angiogenesis is confined to the short period of VEGF expression produced by adenovirus and early gains in collateralization rapidly regress to control levels when VEGF production ceases.",
keywords = "Claudication, Ischemia, Peripheral artery disease, Rabbit, Therapeutic angiogenesis",
author = "Gounis, {M. J.} and Spiga, {M. G.} and Graham, {Regina M} and A. Wilson and S. Haliko and Lieber, {B. B.} and Wakhloo, {A. K.} and Webster, {Keith A}",
year = "2005",
month = "5",
day = "1",
doi = "10.1038/sj.gt.3302481",
language = "English",
volume = "12",
pages = "762--771",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle

AU - Gounis, M. J.

AU - Spiga, M. G.

AU - Graham, Regina M

AU - Wilson, A.

AU - Haliko, S.

AU - Lieber, B. B.

AU - Wakhloo, A. K.

AU - Webster, Keith A

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Therapeutic angiogenesis involves the introduction of exogenous growth factor proteins and genes into ischemic tissues to augment endogenous factors and promote new vessel growth. Positive results from studies in animal models of peripheral arterial disease (PAD) and coronary artery disease over the past decade have supported the implementation of clinical trials testing vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) proteins and genes. Although several clinical trials reported positive results, others have been disappointing and results of a recent Phase II trial of VEGF delivered by adenovirus (the RAVE trial) were negative. It has been suggested that the duration of gene expression following delivery by adenovirus may be insufficient to produce stable vessels. Here we present direct evidence in support of this using the rabbit ischemic hindlimb model injected with adenovirus encoding VEGF165. Immunohistology indicated an activation of endothelial cell cycling and proliferation 2-3 days after VEGF delivery that coincided closely with transient VEGF expression. Ki-67-positive endothelial nuclei were evident at high levels in capillaries and large vessels in muscles from treated animals. Angiography indicated increased density of both large and small vessels in Ad-VEGF-treated muscle at 1 week, but no significant differences thereafter. The early burst of endothelial proliferation was accompanied by increased nuclear fragmentation and condensation in VEGF-treated muscles, suggesting coincident apoptosis. No further endothelial cell proliferation took place after 1 week although there was still evidence of apoptosis. The results suggest that angiogenesis is confined to the short period of VEGF expression produced by adenovirus and early gains in collateralization rapidly regress to control levels when VEGF production ceases.

AB - Therapeutic angiogenesis involves the introduction of exogenous growth factor proteins and genes into ischemic tissues to augment endogenous factors and promote new vessel growth. Positive results from studies in animal models of peripheral arterial disease (PAD) and coronary artery disease over the past decade have supported the implementation of clinical trials testing vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) proteins and genes. Although several clinical trials reported positive results, others have been disappointing and results of a recent Phase II trial of VEGF delivered by adenovirus (the RAVE trial) were negative. It has been suggested that the duration of gene expression following delivery by adenovirus may be insufficient to produce stable vessels. Here we present direct evidence in support of this using the rabbit ischemic hindlimb model injected with adenovirus encoding VEGF165. Immunohistology indicated an activation of endothelial cell cycling and proliferation 2-3 days after VEGF delivery that coincided closely with transient VEGF expression. Ki-67-positive endothelial nuclei were evident at high levels in capillaries and large vessels in muscles from treated animals. Angiography indicated increased density of both large and small vessels in Ad-VEGF-treated muscle at 1 week, but no significant differences thereafter. The early burst of endothelial proliferation was accompanied by increased nuclear fragmentation and condensation in VEGF-treated muscles, suggesting coincident apoptosis. No further endothelial cell proliferation took place after 1 week although there was still evidence of apoptosis. The results suggest that angiogenesis is confined to the short period of VEGF expression produced by adenovirus and early gains in collateralization rapidly regress to control levels when VEGF production ceases.

KW - Claudication

KW - Ischemia

KW - Peripheral artery disease

KW - Rabbit

KW - Therapeutic angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=18744367228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744367228&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302481

DO - 10.1038/sj.gt.3302481

M3 - Article

C2 - 15772688

AN - SCOPUS:18744367228

VL - 12

SP - 762

EP - 771

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 9

ER -